ULK1 PROTAC

ULK1 PROTAC is a targeted protein degradation (TPD) therapeutic being developed by Txinno Bioscience for the treatment of KRAS-mutant cancers, including lung, colorectal, and pancreatic cancers. The molecule functions as a proteolysis-targeting chimera (PROTAC) that recruits an E3 ubiquitin ligase to Unc-51 like autophagy activating kinase 1 (ULK1), leading to its proteasomal degradation. ULK1 is a critical initiator of autophagy, a process that KRAS-mutant cells utilize to survive metabolic stress and escape inhibition of the MAPK pathway. By eliminating ULK1 protein rather than just inhibiting its kinase activity, this approach aims to more effectively block autophagy-mediated resistance mechanisms. The program is currently in the preclinical candidate nomination stage.

Other names

ULK1 degraderULK-1 degraderULK 1 degrader